It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The OX40-OX40L pathway provides crucial co-stimulatory signals for CD4 T cell responses, however the precise cellular interactions critical for OX40L provision in vivo and when these occur, remains unclear. Here, we demonstrate that provision of OX40L by dendritic cells (DCs), but not T cells, B cells nor group 3 innate lymphoid cells (ILC3s), is critical specifically for the effector Th1 response to an acute systemic infection with Listeria monocytogenes (Lm). OX40L expression by DCs is regulated by cross-talk with NK cells, with IFNγ signalling to the DC to enhance OX40L in a mechanism conserved in both mouse and human DCs. Strikingly, DC expression of OX40L is redundant in a chronic intestinal Th1 response and expression by ILC3s is necessary. Collectively these data reveal tissue specific compartmentalisation of the cellular provision of OX40L and define a mechanism controlling DC expression of OX40L in vivo.
The OX40-OX40L axis is a crucial component of the costimulatory requirement of CD4 T cell responses. Here, the authors show context and cell type specific expression of OX40L for driving Th1 cell generation during acute and chronic models of infection.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Fiancette Remi 1 ; Dutton, Emma E 1 ; Willis, Claire 1 ; Rückert Timo 2
; Romagnani Chiara 2
; Gerard, Audrey 3
; Bevington, Sarah L 4 ; MacDonald, Andrew S 5
; Botto, Marina 6
; Vyse, Timothy 7
; Withers, David R 1
1 University of Birmingham, Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, Birmingham, UK (GRID:grid.6572.6) (ISNI:0000 0004 1936 7486)
2 Charité - Universitätsmedizin Berlin, Med. Klinik m.S. Gastroenterologie, Infektiologie und Rheumatologie and Deutsches Rheuma-Forschungszentrum, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)
3 The University of Oxford, The Kennedy Institute of Rheumatology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
4 University of Birmingham, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, Birmingham, UK (GRID:grid.6572.6) (ISNI:0000 0004 1936 7486)
5 University of Manchester, Manchester Collaborative Centre for Inflammation Research, Faculty of Biology, Medicine and Health, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407)
6 Imperial College London, Department of Medicine, Centre for Inflammatory Disease, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
7 King’s College London, Division of Medical and Molecular Genetics and Immunology, Infection and Inflammatory Disease, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)




